A Phase 2/3 interventional study of nalmefene HCl and Placebo in Pathological Gambling, sponsored by Somaxon Pharmaceuticals. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-05-19.
Sponsored by Somaxon Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.
158 studies on the registry are indexed under Gambling; 42 are open to participants now.
This study's enrollment of 233 is above the median of 66 across 128 interventional studies indexed under Gambling.
Browse Gambling studies →Somaxon Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nalmefene HCl 20 mg
Drug: nalmefene HCl
Nalmefene HCl 40 mg
Drug: nalmefene HCl
Placebo
Other: Placebo
Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
Placebo tablet
Assess efficacy in treatment of pathological gambling
Evaluate safety and tolerability in treatment of pathological gambling
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene
Somaxon Pharmaceuticals